Advertisement
Screener

XENON PHARMACEUTICALS INC. (XENE) Income (Loss) from Continuing Operations before Income Taxes, Domestic

2.3 / 5 stars · 37/79 Roast Me

XENON PHARMACEUTICALS INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic

XENON PHARMACEUTICALS INC. (XENE) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$351.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Income Statement › Pre-tax Income

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26

  • XENON PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$351.06M.
  • XENON PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$243.41M.
  • XENON PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$174.49M.
  • XENON PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$121.33M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Domestic 12 month
2025-12-31-$351.06M
10-K · filed 2026-02-26
2024-12-31-$243.41M
10-K · filed 2026-02-26
2023-12-31-$174.49M
10-K · filed 2026-02-26
2022-12-31-$121.33M
10-K · filed 2025-02-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Organon & Co. (OGN)United States$3.603B17.03
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Indivior Pharmaceuticals, Inc. (INDV)$4.250B14.09